Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era

Diva Baggio; Eliza Chung; Cameron Wellard; Neil Waters; Tania Cushion; Geoffrey Chong; Tara Cochrane; Gavin Cull; Pratyush Giri; Nada Hamad; Anna Johnston; Denise Lee; Aarya Murali; Susan Morgan; Stephen Mulligan; Dipti Talaulikar; Sumita Ratnasingam; Erica Wood; Eliza Hawkes; Stephen Opat

doi:10.1111/imj.16445

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era

Diva Baggio, Eliza Chung, Cameron Wellard, Neil Waters, Tania Cushion, Geoffrey Chong, Tara Cochrane, Gavin Cull, Pratyush Giri, Nada Hamad, Anna Johnston, Denise Lee, Aarya Murali, Susan Morgan, Stephen Mulligan, Dipti Talaulikar, Sumita Ratnasingam, Erica Wood, Eliza Hawkes, Stephen Opat

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.

Original language	English
Pages (from-to)	1223-1227
Number of pages	5
Journal	Internal Medicine Journal
Volume	54
Issue number	7
DOIs	https://doi.org/10.1111/imj.16445
Publication status	Published - Jul 2024

Keywords

cancer survivorship
chronic lymphocytic leukaemia
preventive health
registries
skin neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.16445Licence: CC BY-NC

Cite this

Baggio, D., Chung, E., Wellard, C., Waters, N., Cushion, T., Chong, G., Cochrane, T., Cull, G., Giri, P., Hamad, N., Johnston, A., Lee, D., Murali, A., Morgan, S., Mulligan, S., Talaulikar, D., Ratnasingam, S., Wood, E., Hawkes, E., & Opat, S. (2024). Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Internal Medicine Journal, 54(7), 1223-1227. https://doi.org/10.1111/imj.16445

@article{42d692abf06a4f04b1cd7e466d9fc8b3,

title = "Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era",

abstract = "Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.",

keywords = "cancer survivorship, chronic lymphocytic leukaemia, preventive health, registries, skin neoplasms",

author = "Diva Baggio and Eliza Chung and Cameron Wellard and Neil Waters and Tania Cushion and Geoffrey Chong and Tara Cochrane and Gavin Cull and Pratyush Giri and Nada Hamad and Anna Johnston and Denise Lee and Aarya Murali and Susan Morgan and Stephen Mulligan and Dipti Talaulikar and Sumita Ratnasingam and Erica Wood and Eliza Hawkes and Stephen Opat",

note = "Funding Information: Funding: This work is supported by Janssen Pharmaceuticals. Publisher Copyright: {\textcopyright} 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",

year = "2024",

month = jul,

doi = "10.1111/imj.16445",

language = "English",

volume = "54",

pages = "1223--1227",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "Wiley-Blackwell",

number = "7",

}

Baggio, D, Chung, E, Wellard, C, Waters, N, Cushion, T, Chong, G, Cochrane, T, Cull, G, Giri, P, Hamad, N, Johnston, A, Lee, D, Murali, A, Morgan, S, Mulligan, S, Talaulikar, D, Ratnasingam, S, Wood, E , Hawkes, E & Opat, S 2024, 'Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era', Internal Medicine Journal, vol. 54, no. 7, pp. 1223-1227. https://doi.org/10.1111/imj.16445

TY - JOUR

T1 - Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era

AU - Baggio, Diva

AU - Chung, Eliza

AU - Wellard, Cameron

AU - Waters, Neil

AU - Cushion, Tania

AU - Chong, Geoffrey

AU - Cochrane, Tara

AU - Cull, Gavin

AU - Giri, Pratyush

AU - Hamad, Nada

AU - Johnston, Anna

AU - Lee, Denise

AU - Murali, Aarya

AU - Morgan, Susan

AU - Mulligan, Stephen

AU - Talaulikar, Dipti

AU - Ratnasingam, Sumita

AU - Wood, Erica

AU - Hawkes, Eliza

AU - Opat, Stephen

N1 - Funding Information: Funding: This work is supported by Janssen Pharmaceuticals. Publisher Copyright: © 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.

PY - 2024/7

Y1 - 2024/7

N2 - Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.

AB - Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.

KW - cancer survivorship

KW - chronic lymphocytic leukaemia

KW - preventive health

KW - registries

KW - skin neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85197704940&partnerID=8YFLogxK

U2 - 10.1111/imj.16445

DO - 10.1111/imj.16445

M3 - Article

C2 - 38973146

AN - SCOPUS:85197704940

SN - 1444-0903

VL - 54

SP - 1223

EP - 1227

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 7

ER -

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this